Completed Access to Information Requests

Follow:

  • RSS
  • Cite
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 202 record(s)

Req # A-2024-54596

Submission of the Public Health Agency of Canada (PHAC) to the Patented Medicine Prices Review Board’s November 2023 consultation on the Scoping paper of the Board's Guidelines. Submissions from other stakeholders can be viewed here: https://www.canada.ca/en/patented-medicine-prices-review/services/consultations/scoping-paper-board-guidelines.html

Organization: Patented Medicine Prices Review Board Canada

7 page(s)
February 2024

Nothing to report this month

Organization: Patented Medicine Prices Review Board Canada

January 2024

Nothing to report this month

Organization: Patented Medicine Prices Review Board Canada

December 2023

Nothing to report this month

Organization: Patented Medicine Prices Review Board Canada

November 2023

Nothing to report this month

Organization: Patented Medicine Prices Review Board Canada

October 2023

Req # A-2021-024942

Provide all emails sent to/from/cc'ing Douglas Clarke between May 1 to December 16, 2021. Exclude media scans.

Organization: Patented Medicine Prices Review Board Canada

3229 page(s)
September 2023

Req # A-2023-36126

When referring to page numbers below, I mean the pages in the Client Package disclosed under A-2022-05111. Specifically, I would like to request the following: 1. The "Board deck" (presumably a PowerPoint presentation) mentioned on pages 21-27. 2. The powerpoint attached to the email on page 47, which apparently deals with discrepancies between dTCC data. 3. The media lines attached to the email on page 95. 4. The excel sheet attached to the email on page 98. 5. The presentation attached to the email on page 135. 6. Both attachments to the email on page 135, plus the two documents that are linked to in the email: the impact estimates and communication plan. 7. The attachment to the email on page 142. 8. The "Key messages" document linked to in the body of the email on page 145. 9. The Excel file attached to the email on page 165. 10. I would like any contextual documents related to the document which appears on pages 359-360 ("Brochure: 2020 Rent Increase Guidelines). I imagine this was an attachment to an email, in which case I would like the email (possibly pages 4368-4369 of the raw request). I would also like to request any other documents related to how the brochure was located by the PMPRB, or what use was made of the Brochure by the PMPRB (like subsequent email discussions or meeting agendas which list this document, or reports or memos written about this document, etc). In each case, I would like the most recent or final version. I do not need drafts. Please exclude cabinet confidences.

Organization: Patented Medicine Prices Review Board Canada

17 page(s)
September 2023

Nothing to report this month

Organization: Patented Medicine Prices Review Board Canada

August 2023

Req # A-2022-05111

Electronic copies of the following documents. In all cases, cabinet confidences may be excluded and draft versions of documents. In all of the requests below, “draft guidelines” refers to the PMPRB Guidelines that were published for comment on October 6, 2022, or any prior drafts or versions of those 2022 Guidelines (for example, if a draft version was circulated to Health Canada for comment in September 2022, it would be part of the “draft guidelines” for the purpose of this request). • Emails or other communications from Health Canada commenting on the draft guidelines, and that were sent between July 1, 2022, and October 6, 2022. • Emails or other communications from the Board members or Board Chair commenting on the draft guidelines, and that were sent between July 1, 2022, and October 6, 2022. • Any training presentations, training manuals, or summaries of the new guidelines prepared for use by the Board Staff, Board, or other governmental departments prepared between July 1, 2022, and October 6, 2022. • Any documents with calculations of how much prices will decrease under the draft guidelines, or under alternative pricing rules, and that were prepared between January 1, 2022, and October 6, 2022 (note the change in date relative to other requests). • Any documents comparing prices or price reductions under the draft guidelines and the old PMPRB Compendium of Guidelines and Procedures. • Any documents, including legal memos, on the compliance of the draft guidelines with legal decisions about the PMPRB, including Alexion Pharmaceuticals Inc. v. Canada (Attorney General), 2021 FCA 157, Merck Canada c Canada, 2022 QCCA 240, and Innovative Medicines Canada v. Canada (Attorney General), 2020 FC 725. • Any documents which discuss how a medicine’s therapeutic class and comparator products will be established under the draft guidelines. • Any documents showing how the Board Staff arrived at the exact pricing tests discussed in paragraph 33-35 of the draft Guidelines. • Any documents which discuss how Board Staff will assess whether a price is excessive *after* an investigation has been opened. For context, the backgrounder which accompanied the draft guidelines suggested that staff will consider “the totality of the circumstances surrounding the price of the medicine, through the lens of the section 85 factors.

Organization: Patented Medicine Prices Review Board Canada

197 page(s)
July 2023

Req # A-2023-025211

With regard to the c. 2003 HDAP Report on New Patented Drug - Angiomax (http://www.pmprbcepmb.gc.ca/view.asp?ccid=583), I am looking for a copy of any supporting research, reports and calculations used to determine dosage regimens. I am specifically interested in how these quantities (in mL) were derived, the benchmark patient weight that was used (in kg) and the timeframe of the dosing.

Organization: Patented Medicine Prices Review Board Canada

18 page(s)
July 2023

What's new in open government?

Date modified: